Reviva Pharmaceuticals/$RVPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Ticker
$RVPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
14
ISIN
US76152G1004
Website
RVPH Metrics
BasicAdvanced
$39M
-
-$0.76
0.11
-
Price and volume
Market cap
$39M
Beta
0.11
52-week high
$2.62
52-week low
$0.49
Average daily volume
527K
Financial strength
Current ratio
0.544
Quick ratio
0.46
Total debt to equity
-5.029
Interest coverage (TTM)
-1,104.58%
Management effectiveness
Return on assets (TTM)
-178.72%
Return on equity (TTM)
996.17%
Valuation
Price to book
-8.8
Price to tangible book (TTM)
-8.8
Price to free cash flow (TTM)
-1.059
Growth
Earnings per share change (TTM)
-50.49%
3-year earnings per share growth (CAGR)
-4.36%
What the Analysts think about RVPH
Analyst ratings (Buy, Hold, Sell) for Reviva Pharmaceuticals stock.
RVPH Financial Performance
Revenues and expenses
RVPH Earnings Performance
Company profitability
RVPH News
AllArticlesVideos
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
GlobeNewsWire·6 days ago
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·4 weeks ago
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Reviva Pharmaceuticals stock?
Reviva Pharmaceuticals (RVPH) has a market cap of $39M as of June 11, 2025.
What is the P/E ratio for Reviva Pharmaceuticals stock?
The price to earnings (P/E) ratio for Reviva Pharmaceuticals (RVPH) stock is 0 as of June 11, 2025.
Does Reviva Pharmaceuticals stock pay dividends?
No, Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders as of June 11, 2025.
When is the next Reviva Pharmaceuticals dividend payment date?
Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Reviva Pharmaceuticals?
Reviva Pharmaceuticals (RVPH) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.